Key Drivers
- Healthy margins
- Strong FCF
- High intangibles
AIAI Summary
Medtronic has shifted from a steady, cash-flow defensive device conglomerate into an execution-dependent growth story—where successful commercialization of a few high-growth franchises (PFA, Hugo RAS, MiniMed carve‑out and tuck‑ins) and prudent capital allocation will determine whether multiples expand or collapse amid margin pressure, high payout ratio, and goodwill/intangible risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Healthy margins
- •Strong FCF
- •High intangibles
Medtronic pairs strong cash generation, resilient margins and improving leverage that support returns to shareholders, but faces high intangibles, low asset turnover and modest valuation expansion.
Price Behavior
Key Price Behavior Insights:
- •Downward pressure
- •Short-term oversold
- •Defined resistance
MDT is in a short-term downtrend—closing $86.16 on 2026-03-20 about 10.7% below its last month average (~$92.36) after an ~11% drop in the prior 14 trading days, with immediate support near $86.16/$87–$89 and resistance around $92.4 and $96–$99.
~11% decline into $86.16 on 2026-03-20 indicating short-term oversold risk
Sentiment & News
Key News Insights:
- •Dividend maintained
- •MiniMed spin‑off
- •Mixed inflows
Medtronic announced a $0.71 Q4 dividend, completed the MiniMed (MMED) spin-off, engaged analysts at conferences, and showed mixed institutional flows amid broker optimism despite an 11.5% post‑earnings share decline.
Corporate actions and analyst engagement support long‑term shareholder value, but mixed institutional activity and recent share weakness may keep near‑term pressure on the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings